Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 375.0	$ 199.7
Biocon Biologics Transaction		220.0
Payments	263.0	64.1
Reclassifications	0.0	0.0
Accretion	22.7	8.2
Fair value loss (gain)	80.4	11.2
Balance at end of period	215.1	375.0
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	64.4	66.7
Biocon Biologics Transaction		0.0
Payments	43.0	64.1
Reclassifications	54.7	61.8
Accretion	0.0	0.0
Fair value loss (gain)	0.0	0.0
Balance at end of period	76.1	64.4
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	310.6	133.0
Biocon Biologics Transaction		220.0
Payments	220.0	0.0
Reclassifications	(54.7)	(61.8)
Accretion	22.7	8.2
Fair value loss (gain)	80.4	11.2
Balance at end of period	$ 139.0	$ 310.6